主动脉弓动脉粥样硬化在不明来源栓塞性卒中患者中的特征与结局:NAVIGATE ESUS 试验探索性分析
该研究基于 NAVIGATE ESUS 试验中接受经食管超声心动图的 1382 例患者,评估主动脉弓动脉粥样硬化(AAA)的特征、卒中复发率及治疗反应。结果显示 29% 存在 AAA、8% 为复杂 AAA;复杂 AAA 患者年化缺血性卒中复发率为 7.2%,但校正风险评分后未见独立增加复发风险(HR 1.1,95%CI 0.53-2.4),利伐沙班与阿司匹林组各发生 4 例卒中。
要点
- 不明来源栓塞性卒中患者中 AAA 占 29%,复杂 AAA 占 8%。
- 复杂 AAA 与年龄、糖尿病、主动脉瓣病及影像学慢性梗死独立相关。
- 校正风险评分后复杂 AAA 未显示独立增加卒中复发风险。
核心结论
- 复杂 AAA 在 ESUS 患者中常见且与动脉粥样硬化负荷相关,但是否独立增加复发风险尚需进一步研究。
研究设计与样本
- NAVIGATE ESUS 试验的探索性分析,纳入 1382 例接受经食管超声心动图检查的 ESUS 患者。
主要发现
- 1382 例中 397 例(29%)存在 AAA,112 例(8%)为复杂 AAA。
- 复杂 AAA 患者年化缺血性卒中复发率为 7.2%,非复杂 AAA 为 4.2%,无 AAA 为 5.6%。
- 校正风险评分后,复杂 AAA 与卒中复发的风险比为 1.1(95%CI 0.53-2.4)。
- 复杂 AAA 患者中利伐沙班组与阿司匹林组各发生 4 例卒中。
关键数值与推荐
- 复杂 AAA 定义为超声报告为复杂或溃疡性、厚度≥4 mm 或存在活动性血栓。
- 多区域责任梗死比例在复杂 AAA 为 21%、非复杂 AAA 为 17%、无 AAA 为 13%(P=0.07)。
临床怎么用
- 对 ESUS 患者可考虑经食管超声心动图评估 AAA,以识别复杂 AAA 并评估动脉粥样硬化负荷。
- 复杂 AAA 患者抗栓策略选择(利伐沙班 vs 阿司匹林)尚无明确证据支持,需个体化决策。
局限性
- 仅 19% 的参与者接受了经食管超声心动图检查,可能存在选择偏倚。
- 结局事件数量有限,统计效能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Aortic arch atherosclerosis (AAA) is a possible source of embolism in patients with embolic stroke of undetermined source. Previous studies reported high rates of embolic events in patients with AAA, especially those with high-risk AAA. This exploratory analysis of NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial Versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) focused on patients with AAA and assessed their characteristics, stroke recurrence rates, and response to treatment. Methods- The detection of AAA and the assessment of its features were based on transesophageal echocardiography that was done in 19% of participants. AAA plaques were considered to have complex features when reported as complex or ulcerated or were ≥4 mm in thickness or had a mobile thrombus present. Results- Among 1382 participants who had transesophageal echocardiography, 397 (29%) had AAA and 112 (8%) had complex AAA. Mean (SD) age (63 [10] versus 67 [9] versus 69 [9]; P<0.001), prevalence of diabetes mellitus (19% versus 26%, versus 32%; P=0.002), and aortic valvulopathy (10 versus 20 versus 20; P<0.001) increased across no versus noncomplex versus complex AAA, respectively. In multivariable analyses, increasing age, diabetes mellitus, aortic valvulopathy, statin use before randomization, chronic infarcts on imaging, and region were independently associated with any AAA versus no AAA and also with complex AAA versus no AAA. Multiterritorial qualifying infarcts rather than single-territory infarcts were observed in 21% with complex AAA versus 17% noncomplex versus 13% no AAA (P=0.07). Annualized rates of ischemic stroke recurrence were 7.2% versus 4.2% versus 5.6% for complex versus noncomplex versus no AAA, respectively. While prevalence of complex AAA increased with increasing risk score, after adjusting for risk score, we did not observe increased risk of recurrent stroke for patients with complex AAA (hazard ratio, 1.1; 95% CI, 0.53-2.4), although the number of outcomes was limited. In patients with complex AAA, 4 strokes occurred among rivaroxaban-assigned patients and 4 strokes among aspirin-assigned patients. Conclusions- Complex AAA is prevalent in embolic stroke of undetermined source patients and is associated with atherosclerotic burden. Whether complex AAA independently increases recurrent stroke risk and whether a non-vitamin-K oral anticoagulant as compared with aspirin may be effective for reducing recurrent stroke requires additional study. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.
引用
- Ntaios G, Pearce LA, Meseguer E, et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019. PMID: 31526123. doi:10.1161/STROKEAHA.119.025813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。